OncoMatch/Clinical Trials/NCT06768905
Study of IOMAB-ACT Followed by CAR-T Cell Therapy for Patients Relapsed or Refractory (Diffuse Large B-cell Lymphoma
Is NCT06768905 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Iomab-B and CAR-T cell for non hodgkin lymphoma.
Treatment: Iomab-B · CAR-T cell — This study is being done to determine the safety, efficacy and tolerability of a single 50 mCi dose of 131I-Apamistamab given prior to CAR-T cell infusion in patients with Relapsed or refractory (R/R) Diffuse large B-cell lymphoma (DLBCL).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemoimmunotherapy
relapsed or refractory DLBCL or high-grade B-cell lymphoma (HGBL) following at least one or more prior chemoimmunotherapy regimen (with at least one course including an anthracycline and CD20-directed therapy)
Cannot have received: radiopharmaceutical
Patients with prior history of treatment with radiopharmaceuticals for any indication.
Cannot have received: external beam radiation therapy
Exception: except for treatment of cutaneous lesions and localized prostate cancer
Patients with a history of external beam radiation therapy except for treatment of cutaneous lesions and localized prostate cancer.
Lab requirements
Blood counts
Absolute neutrophil count ≥1.0k/µL, Platelets ≥50k/µL, Hemoglobin ≥8g/dL, without requiring blood product or granulocyte-colony stimulating factor support in the 7 days prior to screening and start of 131I-Apamistamab treatment.
Kidney function
Creatinine clearance ≥50 mL/min as calculated by the Cockroft-Gault formula.
Liver function
Total bilirubin ≤1.5x upper limit of normal, AST and ALT ≤3x upper limit of normal (ULN), unless liver dysfunction is thought to be related to underlying malignancy or secondary to Gilbert's disease in which case the direct bilirubin should be ≤3.0 mg/dL, and AST and ALT ≤5x ULN.
Cardiac function
LVEF ≥40% as assessed by echocardiogram or MUGA scan. Exclude NYHA stage III or IV congestive heart failure, myocardial infarction ≤6 months prior to enrollment, any history of clinically significant ventricular arrhythmia or unexplained syncope.
Creatinine clearance ≥50 mL/min as calculated by the Cockroft-Gault formula. Total bilirubin ≤1.5x upper limit of normal , AST and ALT ≤3x upper limit of normal (ULN), unless liver dysfunction is thought to be related to underlying malignancy or secondary to Gilbert's disease in which case the direct bilirubin should be ≤3.0 mg/dL, and AST and ALT ≤5x ULN. Adequate bone marrow function: Absolute neutrophil count ≥1.0k/µL, Platelets ≥50k/µL, Hemoglobin ≥8g/dL. Impaired cardiac function (LVEF <40%) as assessed by echocardiogram or MUGA scan [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Texas Southwestern Medical Center · Dallas, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06768905 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiopharmaceutical, external beam radiation therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify